Cargando…

Targeting anticancer drug-induced senescence in glioblastoma therapy

Detalles Bibliográficos
Autores principales:	Tomicic, Maja T., Christmann, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331026/ https://www.ncbi.nlm.nih.gov/pubmed/30680061 http://dx.doi.org/10.18632/oncotarget.26502

Ejemplares similares

Targeting c-IAP1, c-IAP2, and Bcl-2 Eliminates Senescent Glioblastoma Cells Following Temozolomide Treatment
por: Schwarzenbach, Christian, et al.
Publicado: (2021)

Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?
por: Vilar, Juliana B., et al.
Publicado: (2022)

Oxaliplatin-Induced Senescence in Colorectal Cancer Cells Depends on p14(ARF)-Mediated Sustained p53 Activation
por: Tomicic, Maja T., et al.
Publicado: (2021)

Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination
por: Reich, Thomas R., et al.
Publicado: (2021)

Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics
por: Beltzig, Lea, et al.
Publicado: (2022)

Benzo[a]pyrene represses DNA repair through altered E2F1/E2F4 function marking an early event in DNA damage-induced cellular senescence
por: Allmann, Sebastian, et al.
Publicado: (2020)

Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM
por: Tomicic, Maja T., et al.
Publicado: (2015)

Targeting senescence as an anticancer therapy
por: Bousset, Laura, et al.
Publicado: (2022)

Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells
por: Beltzig, Lea, et al.
Publicado: (2022)

c-Fos is required for excision repair of UV-light induced DNA lesions by triggering the re-synthesis of XPF
por: Christmann, Markus, et al.
Publicado: (2006)

Three prime exonuclease I (TREX1) is Fos/AP-1 regulated by genotoxic stress and protects against ultraviolet light and benzo(a)pyrene-induced DNA damage
por: Christmann, Markus, et al.
Publicado: (2010)

Delayed c-Fos activation in human cells triggers XPF induction and an adaptive response to UVC-induced DNA damage and cytotoxicity
por: Tomicic, Maja T., et al.
Publicado: (2010)

Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
por: Prasanna, Pataje G, et al.
Publicado: (2021)

The Potential of Senescence as a Target for Developing Anticancer Therapy
por: Jo, Hyein, et al.
Publicado: (2023)

Targeted Molecular Therapy in Glioblastoma
por: Festuccia, Claudio, et al.
Publicado: (2020)

Correction to: Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
Publicado: (2022)

Role of Senescence in Tumorigenesis and Anticancer Therapy
por: Stoczynska-Fidelus, Ewelina, et al.
Publicado: (2022)

Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome
por: Reich, Thomas R., et al.
Publicado: (2017)

Exploiting tumor cell senescence in anticancer therapy
por: Lee, Minyoung, et al.
Publicado: (2014)

Special Issue “Anticancer Drugs”
por: Meegan, Mary J., et al.
Publicado: (2019)

Advances in Anticancer Drug Discovery
por: Reynisson, Jóhannes
Publicado: (2021)

Anticancer Platinum Drugs Update
por: Ciarimboli, Giuliano
Publicado: (2021)

Pseudo-resistance to anticancer drugs
por: Davoli, Enrico, et al.
Publicado: (2022)

Targeting anxiety and senescence with senolytics
por: Raffaele, Marco, et al.
Publicado: (2022)

PPARs and Anticancer Therapies
por: Robbins, Michael E. C., et al.
Publicado: (2010)

Adaptive upregulation of DNA repair genes following benzo(a)pyrene diol epoxide protects against cell death at the expense of mutations
por: Christmann, Markus, et al.
Publicado: (2016)

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs
por: Overbeek, J.K., et al.
Publicado: (2023)

Special Issue “Anticancer Drugs 2021”
por: Meegan, Mary J., et al.
Publicado: (2022)

Targeting proteostasis maintenance and autophagy in senescence
por: L’Hôte, Valentin, et al.
Publicado: (2022)

Senescent Cells: A Potential Target for New Cancer Therapies in Older Oncologic Patients
por: Brattinga, Baukje, et al.
Publicado: (2021)

SARS-CoV-2-induced senescence as a potential therapeutic target
por: Denholm, Mary, et al.
Publicado: (2022)

Hypoxia and glioblastoma therapy
por: Yang, Chunzhang, et al.
Publicado: (2015)

Pro-senescence therapy for hepatocellular carcinoma
por: Muehlich, Susanne, et al.
Publicado: (2013)

Cell fusion induced senescence
por: Gal, Hilah, et al.
Publicado: (2014)

Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies
por: Ng, Chau Yee, et al.
Publicado: (2018)

Adverse Reactions to Anticancer Drugs in the Oral Cavity
por: Di Fede, Olga, et al.
Publicado: (2018)

The wisdom of crowds and the repurposing of artesunate as an anticancer drug
por: Augustin, Yolanda, et al.
Publicado: (2015)

Anticancer drug R&D landscape in China
por: Zhao, Shen, et al.
Publicado: (2020)

Senescence of Tumor Cells in Anticancer Therapy—Beneficial and Detrimental Effects
por: Piskorz, Wiktoria Monika, et al.
Publicado: (2022)

Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair
por: Christmann, Markus, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_f084qiva4lv3j99faiaeo1eqdm